[go: up one dir, main page]

CL2008003675A1 - Compounds derived from 5-alkyl or alkenyl 3-cyanopyridines, preparation process, pharmaceutical composition, useful to reduce the increased activity of an enzyme in a mammal, wherein said enzyme is a protein kinase, intended for the treatment of inflammation, asthma, colitis, multiple sclerosis, psoriasis, rheumatoid arthritis. - Google Patents

Compounds derived from 5-alkyl or alkenyl 3-cyanopyridines, preparation process, pharmaceutical composition, useful to reduce the increased activity of an enzyme in a mammal, wherein said enzyme is a protein kinase, intended for the treatment of inflammation, asthma, colitis, multiple sclerosis, psoriasis, rheumatoid arthritis.

Info

Publication number
CL2008003675A1
CL2008003675A1 CL2008003675A CL2008003675A CL2008003675A1 CL 2008003675 A1 CL2008003675 A1 CL 2008003675A1 CL 2008003675 A CL2008003675 A CL 2008003675A CL 2008003675 A CL2008003675 A CL 2008003675A CL 2008003675 A1 CL2008003675 A1 CL 2008003675A1
Authority
CL
Chile
Prior art keywords
enzyme
cyanopyridines
colitis
psoriasis
asthma
Prior art date
Application number
CL2008003675A
Other languages
Spanish (es)
Inventor
Diane Harris Boschelli
Lawrence Nathan Tumey
Niala Bhagirath
Joan Jowen Chen
Jr Middleton Brawner Floyd
Z Li
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CL2008003675A1 publication Critical patent/CL2008003675A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Compuestos derivados de 5-alquil o alquenil 3-cianopiridinas, procedimiento de preparación, composición farmacéutica, útil para reducir la actividad incrementada de una enzima en un mamífero, en donde dicha enzima es una proteína quinasa, destinado al tratamiento de la inflamación, asma, colitis, esclerosis múltiple, soriasis, artritis reumatoide.Compounds derived from 5-alkyl or alkenyl 3-cyanopyridines, preparation process, pharmaceutical composition, useful for reducing the increased activity of an enzyme in a mammal, wherein said enzyme is a protein kinase, intended for the treatment of inflammation, asthma, colitis, multiple sclerosis, psoriasis, rheumatoid arthritis.

CL2008003675A 2007-12-13 2008-12-10 Compounds derived from 5-alkyl or alkenyl 3-cyanopyridines, preparation process, pharmaceutical composition, useful to reduce the increased activity of an enzyme in a mammal, wherein said enzyme is a protein kinase, intended for the treatment of inflammation, asthma, colitis, multiple sclerosis, psoriasis, rheumatoid arthritis. CL2008003675A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1345707P 2007-12-13 2007-12-13

Publications (1)

Publication Number Publication Date
CL2008003675A1 true CL2008003675A1 (en) 2009-03-20

Family

ID=40429261

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008003675A CL2008003675A1 (en) 2007-12-13 2008-12-10 Compounds derived from 5-alkyl or alkenyl 3-cyanopyridines, preparation process, pharmaceutical composition, useful to reduce the increased activity of an enzyme in a mammal, wherein said enzyme is a protein kinase, intended for the treatment of inflammation, asthma, colitis, multiple sclerosis, psoriasis, rheumatoid arthritis.

Country Status (5)

Country Link
EP (1) EP2229377A1 (en)
JP (1) JP2011506475A (en)
CA (1) CA2709314A1 (en)
CL (1) CL2008003675A1 (en)
WO (1) WO2009076602A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101452579B1 (en) 2012-08-17 2014-10-21 주식회사 두산 Novel compound and organic electroluminescent device comprising the same
AR094812A1 (en) * 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd DERIVED FROM MONOCYCLIC PYRIDINE AS AN FGFR INHIBITOR
WO2016027781A1 (en) 2014-08-18 2016-02-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 Salt of monocyclic pyridine derivative and crystal thereof
RU2712222C2 (en) 2015-03-25 2020-01-27 Нэшнл Кэнсер Сентер Therapeutic agent for bile duct cancer
WO2017013593A1 (en) 2015-07-22 2017-01-26 Lupin Limited Isoquinolinone derivatives as parp inhibitors
AU2016374441B2 (en) 2015-12-17 2021-10-21 Eisai R&D Management Co., Ltd. Therapeutic agent for breast cancer
BR112020017922A2 (en) 2018-03-28 2020-12-22 Eisai R&D Management Co., Ltd. THERAPEUTIC AGENT FOR HEPATOCELLULAR CARCINOMA
WO2024151919A1 (en) * 2023-01-13 2024-07-18 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7781591B2 (en) * 2006-06-13 2010-08-24 Wyeth Llc Substituted 3-cyanopyridines as protein kinase inhibitors
AU2006247520A1 (en) * 2005-05-18 2006-11-23 Wyeth 3-cyanoquinoline inhibitors of TPL2 kinase and methods of making and using the same

Also Published As

Publication number Publication date
JP2011506475A (en) 2011-03-03
CA2709314A1 (en) 2009-06-18
WO2009076602A1 (en) 2009-06-18
WO2009076602A8 (en) 2010-02-18
EP2229377A1 (en) 2010-09-22

Similar Documents

Publication Publication Date Title
CL2008003675A1 (en) Compounds derived from 5-alkyl or alkenyl 3-cyanopyridines, preparation process, pharmaceutical composition, useful to reduce the increased activity of an enzyme in a mammal, wherein said enzyme is a protein kinase, intended for the treatment of inflammation, asthma, colitis, multiple sclerosis, psoriasis, rheumatoid arthritis.
CL2008003506A1 (en) Compounds derived from pyrrolo [3,2-d] pyrimidine, inhibitors of pi3 kinase and mtor kinase; Preparation method; Pharmaceutical composition, useful for the treatment of diseases such as atherosclerosis, arthritis, psoriasis and cancer.
CL2008000348A1 (en) COMPOUNDS DERIVED FROM CARBOXAMIDE, INHIBITORS OF THE ACTIVITY OF PROTEIN QUINASA B; PHARMACEUTICAL COMPOSITION; PROCESS TO PREPARE IT; AND USE IN THE TREATMENT OF DISEASES SUCH AS CANCER AND ARTHRITIS.
CL2012001627A1 (en) Compounds derived from 1,3-thiazole-phenylaminopyrimidines, inhibitors of syk; pharmaceutical composition; and its use for the treatment of rheumatoid arthritis and cancer.
CL2011000668A1 (en) Compounds derived from pyrazolopyridine; Preparation process; Pharmaceutical composition and use in the treatment of diseases such as rheumatoid arthritis, psoriasis, multiple sclerosis, among others.
CL2007001282A1 (en) Compounds derived from 2-pyridone; Preparation process; pharmaceutical composition; Preparation process; and use for the treatment of diseases such as pulmonary emphysema, bronchitis, asthma, psoriasis, atherosclerosis, rheumatoid arthritis, among others.
CL2013000391A1 (en) Compounds derived from 6- (2-hydroxymethyl-phenyl) -2-methyl-2h-pyridazin-3-one, bruton tyrosine kinase inhibitors (btk); pharmaceutical composition; method to treat an inflammatory and / or autoimmune condition, rheumatoid arthritis or asthma; and its use to treat an inflammatory and / or autoimmune condition.
BRPI0909040B8 (en) azetidine and cyclobutane derivatives, their uses, and composition
BR112014014809A2 (en) pharmaceutical compositions comprising glitazones and nrf2 activators
AR054336A1 (en) TREATMENT OF DERMATOLOGICAL AND PRURITE DISEASES
BR112012015255A2 (en) "antibody, pharmaceutical composition, use of an antibody, method of treatment, nucleic acid, expression vector, host cell and method of producing a recombinant antibody"
CL2009001151A1 (en) Compounds derived from benzomorphane alicyclic carbocyclic acids, preparation procedure, pharmaceutical composition, useful for treating diseases influenced by the inhibition of the enzyme 11beta-hydroxysteroid dehydrogenase, such as metabolic disorders.
BRPI0817154B8 (en) "method of modifying a yeast cell for ethanol production, modified yeast cell, use of a modified yeast cell and method for ethanol production"
CL2007003774A1 (en) COMPOUNDS DERIVED FROM QUINAZOLINA SUBSTITUTES, INHIBITORS OF QUINASA; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS CANCER, ATEROSCLEROSIS AND ARTHRITIS.
CL2013000930A1 (en) Antibody for interleukin 17 (il-17); use of said antibody to treat psoriasis using il-17 antagonists.
CL2008000670A1 (en) Compounds derived from thiazolidinediones and substituted oxazolidinediones; pharmaceutical composition; process of preparation of the pharmaceutical composition; and use in the treatment of diseases such as rheumatoid arthritis, epoc, cancer, among others.
CL2010001637A1 (en) Compounds derived from isoindolones; pharmaceutical composition comprising them; and its use as mek kinase inhibitors to treat hyperproliferative and / or inflammatory diseases such as cancer, rheumatoid arthritis among others.
NZ593907A (en) Treating collagen-mediated diseases with Clostidium histolyticum collagenase I and II
CL2008000790A1 (en) COMPOUNDS DERIVED FROM REPLACED PURINA; SYNTHESIS METHOD; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF SUCH DISEASES AS ATEROSCLEROSIS, ARTHRITIS, PSORIASIS AND CANCER.
BR112012023660A2 (en) new methods to target cancer stem cells
CL2011001830A1 (en) Crystalline form of n - [(1s) -2-amino-1 - [(3-fluorophenyl) methyl] ethyl] -5-chloro-4- (4-chloro-1-methyl-1h-pyrazole-5- hydrochloride il) -2-thiophenecarboxamide; pharmaceutical composition; pharmaceutical combination; process to prepare the pharmaceutical composition; and its use to treat or reduce a selected disease of cancer and arthritis.
CL2008002185A1 (en) Pyrimidine derived compounds, phosphatidylinositol-3-kinase inhibitors; pharmaceutical composition comprising said compounds; and its use for the treatment of respiratory diseases, allergies, inflammation, cancer, among other diseases.
MX2016000794A (en) High potency pancreatin pharmaceutical compositions.
CL2011001427A1 (en) Compounds derived from 4-azetidinyl-1-heteroaryl-cyclohexanol; pharmaceutical composition; and use in the treatment of diseases such as epoc, atherosclerosis, rheumatoid arthritis, among others.
CL2008003067A1 (en) Compound 2- [3- (2,2-Difluoro-benzo [1,3] dioxol-5-ylamino) -5- (2,6-dimethyl-pyridin-4-yl) - [1,2,4] triazole -1-yl] -n-ethyl-acetamide, alpha-7 nicotinic receptor modulator; Preparation process; pharmaceutical composition and its preparation process; and its use in the treatment of psychotic, intellectual, inflammatory disorders.